Trueblood Wealth Management LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Trueblood Wealth Management LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 4,786 shares of the biopharmaceutical company’s stock, valued at approximately $388,000.

Other hedge funds also recently made changes to their positions in the company. Altshuler Shaham Ltd raised its stake in Gilead Sciences by 7.0% in the 4th quarter. Altshuler Shaham Ltd now owns 1,856 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 121 shares during the period. Nilsine Partners LLC increased its position in shares of Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after buying an additional 127 shares during the period. Etesian Wealth Advisors Inc. increased its position in shares of Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after buying an additional 128 shares during the period. Revolve Wealth Partners LLC increased its position in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 130 shares during the period. Finally, Rodgers Brothers Inc. grew its holdings in shares of Gilead Sciences by 4.6% during the second quarter. Rodgers Brothers Inc. now owns 3,113 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 138 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Up 0.3 %

Shares of NASDAQ GILD traded up $0.24 during trading hours on Thursday, hitting $73.25. 8,356,921 shares of the company traded hands, compared to its average volume of 7,612,797. The company’s 50 day moving average price is $75.11 and its 200 day moving average price is $77.29. The stock has a market capitalization of $91.20 billion, a price-to-earnings ratio of 16.40, a price-to-earnings-growth ratio of 0.92 and a beta of 0.18. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12 month low of $71.37 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business had revenue of $7.12 billion during the quarter, compared to the consensus estimate of $7.10 billion. During the same period last year, the company earned $1.67 EPS. The business’s revenue was down 3.7% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.07 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be given a dividend of $0.77 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date is Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.20%. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on GILD. Cantor Fitzgerald decreased their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Wells Fargo & Company decreased their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Oppenheimer reduced their price target on shares of Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, February 12th. Royal Bank of Canada cut their target price on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. Finally, Mizuho cut their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Hold” and a consensus target price of $85.36.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the sale, the insider now directly owns 100,936 shares in the company, valued at $7,386,496.48. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Johanna Mercier sold 8,242 shares of the stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total value of $702,465.66. Following the completion of the sale, the insider now owns 82,729 shares of the company’s stock, valued at $7,050,992.67. The disclosure for this sale can be found here. Insiders sold 15,242 shares of company stock worth $1,277,726 in the last three months. 0.16% of the stock is owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.